How One Drug Changed Diabetes Forever - Let's Talk About Hormones
Study record managers: refer to the Data Element Definitions if submitting registration or results information. Most patients with metastatic disease who were managed with ADT eventually progress to castration-resistant prostate cancer CRPC and die of the disease. CRPC can be treated with docetaxel, abiraterone plus prednisone, enzalutamide, and cabazitaxel, which provide limited survival benefits.
Thus, Metformin Prostatakrebs is still a need to improve the therapeutic options available for advanced-stage prostate cancer patients. Targeting therapy-resistant cancer stem cells Metformin Prostatakrebs in prostate cancer provides a unique opportunity for novel therapeutic interventions.
Metformin, a common well-tolerated oral Metformin Prostatakrebs prescribed for type II diabetes, could be used to sensitize prostate CSCs to current conventional anticancer therapies and improve the efficacy of treatment. Some studies reported that Metformin could enhance the effectiveness of ADT. Metformin augmented the Metformin Prostatakrebs and apoptotic effects of ADT in prostate cancer. The combination of these two drugs significantly Metformin Prostatakrebs prostate Metformin Prostatakrebs cell growth compared to monotherapy with either drug.
Also, metformin might reduce the development of CRPC. Metformin Prostatakrebs studies showed that obesity and DM were linked to aggressive prostate cancer phenotype, including biochemical failure after radical prostatectomy and external beam radiotherapy with higher incidence of complications of ADT.
Interestingly, metformin reduces the incidence of diabetes Metformin Prostatakrebs the adverse metabolic effects of ADT, including hyperinsulinaemia and dyslipidaemia, and decreases myocardial infarction risk and prolongs survival in diabetic patients.
To the best of our knowledge, after extensive computer research, there is no published results from prospective randomized trials evaluating role of metformin among men with high risk locally advanced or metastatic prostate cancer patients who will start Metformin Prostatakrebs with ADT.
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.
For general information, Metformin Prostatakrebs About Clinical Studies. High-risk newly diagnosed non-metastatic node-negative disease at least two of:. OR newly diagnosed metastatic or node-positive disease at least one of:.
Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms x. Save this study. Warning You have reached the maximum number of saved studies Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer Mansmed The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Listing a study does not mean it has been evaluated by the U. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details. Last Update Posted : May 2, See Contacts and Locations. Study Description. This study evaluate the addition of metformin to standard of care in locally advanced and metastatic prostate cancer, half the patient will receive metformin in combination with standard treatment, and the other half will receive the standard of care only.
FDA Resources. Arms and Interventions. Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to Metformin Prostatakrebs cases.
The starting daily dose of metformin is mg Once daily, to be increased to mg if tolerated. Patients will Metformin Prostatakrebs according to Standard of care only. Outcome Measures. Number of overall survivors at 4 years regardless occurrence of CRPC or not. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important Metformin Prostatakrebs decision. Patients with a history of lactic acidosis Patient treated for a cancer other than prostate cancer, with the exception of basal cell carcinoma Acute or chronic metabolic acidosis.
Patients suffering from severe Metformin Prostatakrebs. Patients with chronic heart failure. Patients with hepatic impairment. Patients with severe Metformin Prostatakrebs disease. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor Metformin Prostatakrebs contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials. Layout Metformin Prostatakrebs for location contacts Contact: Reham Alghandour Rehamalghandour mans. More Information. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Prostate Cancer Prostatic Dis. Epub May Understanding the benefit of metformin use in Metformin Prostatakrebs treatment. BMC Med. Short-term Metformin Prostatakrebs of metformin in type 2 diabetes.
Diabetes Obes Metab. Hamilton RJ. Metformin for castrate-resistant prostate cancer: learning more about an old dog's new tricks. Eur Urol. Epub Jan A review for clinicians: Prostate cancer and the antineoplastic properties of metformin. Urol Oncol. Epub Nov 9. Metformin and prostate cancer stem cells: a novel therapeutic target.
Epub Jul Cancer Med. Epub Jan 4. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. Epub Mar Metformin kills and radiosensitizes cancer Metformin Prostatakrebs and preferentially kills cancer stem cells. Sci Rep. Epub Apr Spratt, Chi Zhang, Zachary S. Metformin Prostatakrebs Urol ; EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Epub Nov Metformin Prostatakrebs Metformin, prostate cancer. National Library of Medicine U. National Institutes of Health U. Department of Health and Metformin Prostatakrebs Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Prostate Cancer. Drug: Metformin. Phase 2. Study Type :. Estimated Enrollment :.
Actual Study Start Date :. Estimated Primary Completion Date :. Estimated Study Completion Date :. Active Comparator: Investigational arm Metformin will be added to standard Metformin Prostatakrebs care. Drug: Metformin Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose Metformin Prostatakrebs metformin is mg Once daily, to be increased to mg if tolerated Other Name: Cidophage.
No Intervention: Control arm Patients will treated according to Standard of care only. Rehamalghandour mans. Elshalam hotmail. Reham Algahndour, Assistant lecturer, Mansoura University.